KRAS mutations were more prevalent in mucinous carcinoma than in adenocarcinoma or signet-ring cell carcinoma (72.0% vs 39.0% vs 57.1%, P = .006). The gene discussed is KRAS; the disease is signet ring cell carcinoma.